At the recent American Society of Hematology (ASH) annual meeting, phase II data were presented on a bispecific antibody for ...

Genentech, a subsidiary of the Roche Group, has received the US Food and Drug Administration’s (FDA) accelerated approval for ...

The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...

Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...

Follicular lymphoma is often underrecognized not only for its clinical complexity but also for the significant financial ...

The addition of epcoritamab to standard therapy significantly improved PFS for patients with relapsed or refractory follicular lymphoma, according to study results presented at ASH Annual Meeting and ...

The FDA approved epcoritamab plus R 2 on November 18 for the treatment of patients with relapsed or refractory FL. It also ...

While both women and men may experience classic symptoms of lymphoma, women may have different symptoms if the lymphoma has developed in a reproductive organs. Lymphoma is a type of cancer that ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the best stocks to buy for the next 5 years. On December 15, Goldman Sachs ...

Ever the fighter, he never gave up,” Frank Cozzolino’s daughter Filomena wrote in a tribute shared on Instagram. The HGTV ...

New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular lymphoma can achieve durable, multi-year remission with chimeric antigen receptor ...

Miami Hurricanes guard Marcus Allen will miss the rest of the 2025-2026 season as he undergoes treatment for non-Hodgkin ...